Braveheart Investment Group PLC (AIM:BRH) shares soared by a third on Wednesday following a promising update on two of its primary investments.
Kirkstall Limited, 86% owned by Braveheart, appointed Beijing Kilby Biotechnology (BKB) as exclusive distributor for Quasi Vivo products in China.
BKB intends to conduct an 18-month sales campaign.
Meanwhile, wholly owned Paraytec confirmed that its CX300 instrument can detect gram-negative bacteria in human blood in approximately 90 minutes, a significant improvement over the current gram test, which takes between 24 and 48 hours.
Investors gave this update a resounding thumbs up, pushing Braveheart shares up 335 to 5.32p.